Your browser doesn't support javascript.
loading
Discovery of a potent FKBP38 agonist that ameliorates HFD-induced hyperlipidemia
Acta Pharmaceutica Sinica B ; (6): 3542-3552, 2021.
Article de En | WPRIM | ID: wpr-922423
Bibliothèque responsable: WPRO
ABSTRACT
The mammalian target of rapamycin (mTOR)-sterol regulatory element-binding proteins (SREBPs) signaling promotes lipogenesis. However, mTOR inhibitors also displayed a significant side effect of hyperlipidemia. Thus, it is essential to develop mTOR-specific inhibitors to inhibit lipogenesis. Here, we screened the endogenous inhibitors of mTOR, and identified that FKBP38 as a vital regulator of lipid metabolism. FKBP38 decreased the lipid content
Mots clés
Texte intégral: 1 Indice: WPRIM langue: En Texte intégral: Acta Pharmaceutica Sinica B Année: 2021 Type: Article
Texte intégral: 1 Indice: WPRIM langue: En Texte intégral: Acta Pharmaceutica Sinica B Année: 2021 Type: Article